Tolak Shortage: What Providers and Prescribers Need to Know in 2026

While Tolak (fluorouracil 4% cream) is not on the FDA's formal drug shortage list as of 2026, prescribers in dermatology and primary care settings continue to report that patients face real-world access challenges. Understanding the underlying barriers, available alternatives, and patient assistance options can help providers set appropriate expectations and minimize treatment delays.

Clinical Background: What Is Tolak?

Tolak is a brand-name topical formulation of fluorouracil at 4% concentration (40 mg per gram), manufactured by Hill Dermaceuticals, Inc. It is FDA-indicated for the topical treatment of actinic keratosis (AK) lesions of the face, ears, and scalp. The recommended regimen is once-daily application for 4 weeks, distinguishing it from Efudex (fluorouracil 5%), which is typically applied twice daily.

As a nucleoside metabolic inhibitor (antimetabolite), fluorouracil interferes with DNA and RNA synthesis in rapidly proliferating cells. The 4% concentration in Tolak was developed to provide therapeutic efficacy with a once-daily regimen — a meaningful convenience improvement for patient adherence compared to twice-daily alternatives.

The Access Challenge: Why Patients Can't Fill Tolak Prescriptions

The challenges patients face in filling Tolak prescriptions stem from several converging factors:

1. No Generic Equivalent

There is no FDA-approved generic formulation of fluorouracil at the 4% concentration. While generic fluorouracil 5% cream is widely available, it is not substitutable for Tolak under most state pharmacy regulations without a new prescription. This limits the pharmacist's ability to offer a lower-cost alternative when Tolak is unavailable, placing the resolution back in the prescriber's hands.

2. Formulary Placement and Prior Authorization Requirements

Many commercial payers and Part D plans place Tolak on Tier 3 or Tier 4 of their formularies, or require prior authorization. Some plans also require step therapy — meaning the patient must fail on generic fluorouracil 5% or another AK therapy before Tolak will be approved. This is important to communicate to patients at the time of prescribing, as it can add days to weeks of delay.

To minimize delays, consider:

• Submitting the prior authorization at the time of prescribing, not waiting for the pharmacy to alert the patient
• Having staff check formulary status at the point of care using real-time benefit tools if available in your EHR
• Providing patients with the Hill Derm pharmacy cash-pay option ($40 including shipping) as a fallback if insurance issues arise

3. Retail Pharmacy Stocking Gaps

Tolak is not routinely stocked at many large chain pharmacies. Without a pattern of consistent demand at a given location, the pharmacy's ordering algorithm may not reorder Tolak automatically. Independent pharmacies and dermatology-affiliated pharmacies tend to have better availability for specialty dermatology products.

Clinically Appropriate Alternatives When Tolak Is Unavailable

When Tolak is inaccessible or prior authorization is denied, the following alternatives are supported by clinical evidence for treatment of actinic keratosis:

• Fluorouracil 5% cream (Efudex / generic): Same mechanism; widely available; generic available for ~$29-37 with GoodRx coupons. Apply BID for 2-6 weeks. Consider for patients with concurrent superficial basal cell carcinoma.
• Fluorouracil 0.5% cream (Carac): Lower concentration; once-daily dosing; may be better tolerated by patients with sensitive skin or smaller lesion burden.
• Tirbanibulin 1% ointment (Klisyri): Once-daily for 5 days; microtubule inhibitor and Src kinase inhibitor; approved for AK on face or scalp. Good option for adherence-challenged patients or those with DPD deficiency.
• Imiquimod 5% cream (Aldara / generic): Immune response modifier; alternative mechanism; applied 2-3 times per week for multiple weeks. Consider for patients who cannot tolerate fluorouracil.
• In-office procedures: Cryotherapy and photodynamic therapy (PDT) are appropriate for patients with isolated or widespread AKs respectively, and do not depend on pharmacy access.

Special Populations: Key Prescribing Considerations for Tolak

When prescribing or transitioning patients between AK therapies, keep these Tolak-specific considerations in mind:

• DPD deficiency: Contraindicated. Life-threatening systemic toxicity (severe abdominal pain, bloody diarrhea, neutropenia, thrombocytopenia) has been reported in DPD-deficient patients using topical fluorouracil. These patients should receive tirbanibulin, imiquimod, or an in-office procedure instead.
• Pregnancy: Tolak is Pregnancy Category X and is contraindicated. Cases of miscarriage and birth defects (including cleft lip and palate, ventricular septal defect) have been reported with topical fluorouracil exposure during pregnancy.
• Peanut allergy: Tolak contains peanut oil. Contraindicated in patients with peanut allergy. Generic fluorouracil 5% does not contain peanut oil.

How medfinder Can Help Your Patients

For patients who are having difficulty locating Tolak at their local pharmacy, medfinder for providers is a service that contacts pharmacies near the patient to identify which ones have the medication in stock. The patient provides their medication name, dosage, and ZIP code, and medfinder delivers the results by text — eliminating the hours patients might spend calling pharmacies themselves.